Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mammography pushback continues

This article was originally published in The Gray Sheet

Executive Summary

The American College of Radiology and the Society of Breast Imaging are pressing the Senate to add a specific exclusion for mammography in sections of its health care reform bill that rely on recommendations from the U.S. Preventive Services Task Force. The efforts come in response USPSTF's recent recommendation against routine mammograms in average-risk women aged 40-49 and for only biennial scans after that, which ACR and other clinical groups say are misguided (1"The Gray Sheet" Nov. 23, 2009). Nothing in current law or in the pending health care reform bills would require public or private payers to restrict coverage based on the new recommendations, but ACR worries that various provisions in the Senate reform bill would leave openings in that direction. One provision, for instance, gives CMS authority to modify coverage of certain preventive services "to the extent that such modification is consistent with the recommendations of the [USPSTF]" and others only require private payers and Medicaid to cover preventive services if USPSTF recommends them

You may also be interested in...

Task Force Mammography Guidelines Present Challenges And Opportunities

Mammography coverage policies among public and private payers are not likely to be restricted, at least in the near term, by the U.S. Preventive Services Task Force's new breast cancer screening guidelines, but prospects for longer-term adjustments remain

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts